Nasus Pharma Secures Health Canada Approval To Start Phase 2 Clinical Trial Of NS002 Intranasal Epinephrine Powder

Nasus Pharma Ltd., a clinical-stage pharmaceutical company focused on developing innovative intranasal therapies for emergency medical conditions, announced that it has received a No-Objection Letter from Health Canada, the country’s primary regulatory authority for drugs and medical products. The authorization allows the company to proceed with its planned Phase 2 clinical study of NS002, an investigational intranasal epinephrine powder formulation designed for the treatment of anaphylaxis.

The No-Objection Letter from Health Canada represents a key regulatory milestone in the development of NS002. It confirms that the proposed study design, supporting safety data, and manufacturing details provided by Nasus Pharma meet the necessary regulatory requirements. This clearance enables the company to move forward with the next phase of clinical evaluation for NS002.

Dan Teleman, Chief Executive Officer of Nasus Pharma, expressed optimism about the approval, stating that it marks an important step toward transforming anaphylaxis treatment. He explained that for millions of people living with severe allergies, the fear of needles and the inconvenience of carrying autoinjectors often result in poor adherence and delayed treatment during emergencies, which can have life-threatening consequences. 

The upcoming Phase 2 study will further assess the safety and effectiveness of NS002, which utilizes Nasus Pharma’s proprietary Nasax technology to deliver epinephrine as a dry powder through a nasal spray. Teleman added that the company looks forward to initiating the study soon and advancing its mission to provide patients with a faster, more convenient, and user-friendly treatment option for severe allergic reactions.